Blood markers may reveal which lung cancer patients stay Cancer-Free after treatment

NCT ID NCT05415358

Ongoing Knowledge-focused Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 23 people with advanced non-small cell lung cancer who have finished at least 20 months of immunotherapy. Researchers collect blood and tissue samples to look for DNA and immune system markers that might predict if the cancer will come back within 6 months. The goal is to find better ways to monitor patients after treatment ends.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors know which lung cancer patients are at risk of their cancer returning after stopping immunotherapy, leading to better follow-up care.
What could go wrong: This is a small, early-stage study with only 23 participants. It is observational, so it won't test a new treatment. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER, NONSMALL CELL

Contacts and locations

Locations

Atrium Health Levine Cancer

Charlotte, North Carolina, 28204, United States
Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.